Net Renal Drug Secretion Critically Requires Significant Contribution of Basal Uptake Transporters: Perspective From Mechanistic Kidney Model Simulation and Integration of Clinical and In Vitro Data
- 1Faculty of Pharmacy Keio University Tokyo Japan
- 2Genomembrane Co. Ltd Yokohama Kanagawa Japan
- 3iHuman Institute ShanghaiTech University Shanghai China
Abstract
Renal clearance (CL r ) is the net outcome of glomerular filtration, secretion, and reabsorption, which makes the quantitative requirements for net renal secretion difficult to infer from simple clearance models. Using a mechanistic kidney model (MechKiM), we simulated blood‐referenced CL r (CL r,b ) for 30,000 virtual drugs (neutral, monoanionic, and monocationic) under continuous infusion and across all eight combinations of three proximal‐tubule transporters (basal uptake, basal efflux, apical efflux). Net renal secretion (clearance ratio CR = CL r,b /(f
u,b × GFR) > 1.5, where f
u,b and GFR are the unbound fraction in blood and the glomerular filtration rate) occurred only when basal uptake transport was present; apical efflux alone produced proximal secretion that was offset by downstream reabsorption, yielding no net secretion. In the scenario where all three transporters were present within the MechKiM framework, five quantitative criteria distinguished secretion‐type drugs, including basal transporter‐mediated uptake (> 4.2 L/h) and its fractional contribution to total basal uptake (> 94% for non‐cationic compounds). Clinical CL r,p (plasma‐referenced CL r ) versus in vitro uptake‐transporter data (n = 217) and published MechKiM‐PBPK models (n = 19, typically assigning > 99% of basal uptake to transporters) were consistent with these findings. A sufficient contribution of basal uptake transporters in the proximal tubule is essential for observing net renal secretion. This study provides quantitative, in vitro‐translatable criteria to anticipate renal secretion and transporter‐mediated drug–drug interaction liability.
Related
- Multifaceted Food Effects on Intestinal Drug Uptake Transporters: Mechanistic Insights from Small Molecules to Macromolecules
- Mechanistic PBPK Modeling of Antibody–Drug Conjugates: Integration of Antibody Disposition, Linker Deconjugation, and Payload Pharmacokinetics
- Early mobilization in neurocritical care as a threshold-regulated intervention: a narrative review of mechanistic integration and implications for neurological recovery and physiological stability
- Associations Among family environment, self-identity, cognitive emotion regulation strategy use, and physical activity in adolescents: A multi-theory integration perspective
- Microglia replacement therapy for neurological diseases: a mechanistic perspective focused on the Golgi apparatus.
BibTeX
@article{tsuchitani2026renal,
title = {{Net Renal Drug Secretion Critically Requires Significant Contribution of Basal Uptake Transporters: Perspective From Mechanistic Kidney Model Simulation and Integration of Clinical and In Vitro Data}},
author = {Toshiaki Tsuchitani and Masatoshi Tomi and Yuichi Sugiyama},
journal = {CPT: Pharmacometrics \& Systems Pharmacology},
year = {2026},
month = sep,
doi = {10.1002/psp4.70336},
url = {https://doi.org/10.1002/psp4.70336},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Net Renal Drug Secretion Critically Requires Significant Contribution of Basal Uptake Transporters: Perspective From Mechanistic Kidney Model Simulation and Integration of Clinical and In Vitro Data
AU - Toshiaki Tsuchitani
AU - Masatoshi Tomi
AU - Yuichi Sugiyama
PY - 2026
DA - 2026/09/07
JO - CPT: Pharmacometrics & Systems Pharmacology
DO - 10.1002/psp4.70336
UR - https://doi.org/10.1002/psp4.70336
AB - Renal clearance (CL r ) is the net outcome of glomerular filtration, secretion, and reabsorption, which makes the quantitative requirements for net renal secretion difficult to infer from simple clearance models. Using a mechanistic kidney model (MechKiM), we simulated blood‐referenced CL r (CL r,b ) for 30,000 virtual drugs (neutral, monoanionic, and monocationic) under continuous infusion and across all eight combinations of three proximal‐tubule transporters (basal uptake, basal efflux, apical efflux). Net renal secretion (clearance ratio CR = CL r,b /(f u,b × GFR) > 1.5, where f u,b and GFR are the unbound fraction in blood and the glomerular filtration rate) occurred only when basal uptake transport was present; apical efflux alone produced proximal secretion that was offset by downstream reabsorption, yielding no net secretion. In the scenario where all three transporters were present within the MechKiM framework, five quantitative criteria distinguished secretion‐type drugs, including basal transporter‐mediated uptake (> 4.2 L/h) and its fractional contribution to total basal uptake (> 94% for non‐cationic compounds). Clinical CL r,p (plasma‐referenced CL r ) versus in vitro uptake‐transporter data (n = 217) and published MechKiM‐PBPK models (n = 19, typically assigning > 99% of basal uptake to transporters) were consistent with these findings. A sufficient contribution of basal uptake transporters in the proximal tubule is essential for observing net renal secretion. This study provides quantitative, in vitro‐translatable criteria to anticipate renal secretion and transporter‐mediated drug–drug interaction liability.
SN - 2163-8306
ER -